Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Gefitinib”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableStudy completedNCT01130961
What this trial is testing

Management of Advanced Non-Small Cell Lung Cancer (NSCLC) and Clinical Outcomes in Patients Who Received Gefitinib in Thailand

Who this might be right for
Lung Cancer
AstraZeneca 104
Large-scale testing (Phase 3)UnknownNCT01158170
What this trial is testing

Prophylactic Cranial Irradiation in Erlotinib/Gefitinib-responders With Non-small Cell Lung Cancer (NSCLC) (RT1001)

Who this might be right for
Non-small Cell Lung Cancer
Zhejiang Cancer Hospital 200
Testing effectiveness (Phase 2)WithdrawnNCT00268255
What this trial is testing

Gefitinib and Radiation Therapy in Treating Patients With Inoperable Stage I or Stage II Non-Small Cell Lung Cancer

Who this might be right for
Non-small Cell Lung Cancer
Barbara Ann Karmanos Cancer Institute
Testing effectiveness (Phase 2)Ended earlyNCT00493025
What this trial is testing

Paclitaxel, Cisplatin, Gefitinib, and Radiation Therapy Followed by Surgery and Gefitinib in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction That Can Be Removed By Surgery

Who this might be right for
Esophageal Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 19
Testing effectiveness (Phase 2)Study completedNCT00014144
What this trial is testing

S0031, ZD 1839 in Treating Patients With Advanced Cancer of the Urinary Tract

Who this might be right for
Bladder CancerTransitional Cell Cancer of the Renal Pelvis and UreterUrethral Cancer
SWOG Cancer Research Network 31
Testing effectiveness (Phase 2)UnknownNCT01192243
What this trial is testing

Study of Gefitinib Compared With Pemetrexed/Cisplatin in Advanced Non-Small Cell Lung Cancer Patients

Who this might be right for
ToxicityNon-small Cell Lung Cancer
Fudan University 68
Testing effectiveness (Phase 2)Study completedNCT00239343
What this trial is testing

Phase II Trial of Preoperative Therapy With Gefitinib and Chemotherapy in Patients With ERneg Breast Cancer

Who this might be right for
Breast Cancer
AstraZeneca 160
Testing effectiveness (Phase 2)Study completedNCT00137761
What this trial is testing

Docetaxel in Combination With Iressa in Previously Treated Patients With Pancreatic Cancer

Who this might be right for
Metastatic Pancreatic Carcinoma
Dana-Farber Cancer Institute 32
Large-scale testing (Phase 3)Study completedNCT00080340
What this trial is testing

Study of TLK286 (Telcyta) vs. Gefitinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Who this might be right for
Non Small Cell Lung Carcinoma
Telik 520
Testing effectiveness (Phase 2)UnknownNCT03267654
What this trial is testing

Gefitinib With Chemotherapy or Anti-angiogenesis in NSCLC Patients With Bim Deletion or Low EGFR Mutation Abundance

Who this might be right for
Non-small-cell Lung Cancer
Qilu Pharmaceutical Co., Ltd. 100
Testing effectiveness (Phase 2)Study completedNCT00242918
What this trial is testing

Safety and Effectiveness Study of Docetaxel and ZD1839 Followed by Removal of the Prostate to Treat Prostate Cancer

Who this might be right for
Prostate Cancer
Benaroya Research Institute 29
Testing effectiveness (Phase 2)Study completedNCT01982955
What this trial is testing

Tepotinib With Gefitinib in Participants With Locally Advanced or Metastatic NSCLC (INSIGHT)

Who this might be right for
Non-small Cell Lung Cancer
Merck KGaA, Darmstadt, Germany 88
Testing effectiveness (Phase 2)Study completedNCT00229723
What this trial is testing

IRESSA™ (Gefitinib) With Cisplatin Plus Radiotherapy for the Treatment of Previously Untreated Unresected Late Stage III/IV Non-Metastatic Head and Neck Squamous Cell Carcinoma

Who this might be right for
Neoplasms, Squamous Cell
AstraZeneca 224
Testing effectiveness (Phase 2)Study completedNCT00258323
What this trial is testing

Radiotherapy,Chemotherapy,Before and After Surgery in Advanced Esophageal or Gastroesophageal Junction Cancer

Who this might be right for
Esophageal Cancer
Case Comprehensive Cancer Center 80
Testing effectiveness (Phase 2)Ended earlyNCT00258297
What this trial is testing

Gefitinib in Treating Patients With Stage I, Stage II, or Stage III Esophageal Cancer That Can Be Removed By Surgery

Who this might be right for
Esophageal Cancer
University of Rochester 30
Testing effectiveness (Phase 2)UnknownNCT01510990
What this trial is testing

First Line Gefitinib by FDG-PET Metabolic Response

Who this might be right for
Non-small Cell Lung Cancer
Asan Medical Center 60
Not applicableApproved For MarketingNCT00684385
What this trial is testing

An Expanded Access Programme With Iressa for Patients With Non-Small-Cell Lung Cancer and Cancer of the Head and Neck

Who this might be right for
Non Small Cell Lung CancerCancer of the Head and Neck
AstraZeneca
Testing effectiveness (Phase 2)Ended earlyNCT01189435
What this trial is testing

Erlotinib Re-Challenge for Recurrent EGFR-mutant Lung Cancer in Patients Who Previously Received Adjuvant Erlotinib or Gefitinib

Who this might be right for
Lung Cancer
Memorial Sloan Kettering Cancer Center 2
Early research (Phase 1)Study completedNCT00027625
What this trial is testing

Gefitinib Plus Temozolomide in Treating Patients With Malignant Primary Glioma

Who this might be right for
Brain and Central Nervous System Tumors
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Testing effectiveness (Phase 2)UnknownNCT01027676
What this trial is testing

Study of Vorinostat and Gefitinib in Relapsed/ or Refractory Patients With Advanced Non-small Cell Carcinoma (NSCLC)

Who this might be right for
Non-Small-Cell Lung Carcinoma
National Cancer Center, Korea 50
Next Page